infect
may
hazard
health
mother
cours
pregnanc
unborn
child
lead
prematur
labor
prematur
ruptur
membran
therebi
increas
risk
spontan
abort
prematur
furthermor
certain
germ
pass
unborn
child
harm
directli
therefor
antiinfect
treatment
effect
safe
mother
unborn
child
often
requir
use
penicillin
older
cephalosporin
well
document
consid
safe
consequ
drug
choic
pregnanc
select
case
bacteri
resist
intoler
firstlin
antibiot
antiinfect
agent
might
recommend
especi
lifethreaten
infect
therapi
welltri
agent
might
need
potenti
benefit
treatment
case
often
outbal
potenti
risk
unborn
child
stephani
padberg
erythromycin
macrolid
pharmacolog
erythromycin
macrolid
inhibit
bacteri
protein
synthesi
bacteriostat
macrolid
primarili
appli
treatment
infect
gramposit
germ
also
effect
haemophilu
influenza
intracellular
pathogen
chlamydia
macrolid
offer
altern
patient
penicillin
allergi
erythromycin
oldest
medic
group
resorpt
delay
third
trimest
gastrointestin
side
effect
lead
lower
therapeut
plasma
concentr
result
treatment
failur
larsen
matern
erythromycin
concentr
obtain
fetu
therefor
erythromycin
suffici
reliabl
drug
fetal
amniot
infect
newer
macrolid
antibiot
azithromycin
clarithromycin
dirithromycin
josamycin
midecamycin
roxithromycin
troleandomycin
similar
antibacteri
spectrum
erythromycin
degre
less
gastrointestin
side
effect
spiramycin
use
toxoplasmosi
first
trimest
telithromycin
first
ketolid
antibiot
clinic
use
structur
relat
erythromycin
erythromycin
alway
consid
safe
effect
antibiot
pregnanc
data
sever
thousand
first
trimest
exposur
support
associ
erythromycin
congenit
malform
eg
czeizel
howev
analysi
data
swedish
birth
registri
show
weakli
signific
increas
malform
children
whose
mother
took
erythromycin
earli
pregnanc
compar
offspr
whose
mother
use
phenoxymethylpenicillin
base
increas
rate
cardiovascular
malform
especi
ventricular
atrial
septal
defect
updat
swedish
data
verifi
associ
use
erythromycin
earli
pregnanc
cardiovascular
defect
increas
incid
pylor
stenosi
discuss
author
observ
intrauterin
exposur
first
trimest
biolog
plausibl
mention
link
suggest
neonat
treatment
erythromycin
first
two
week
develop
pyloru
stenosi
eg
mahon
studi
fail
find
higher
rate
septum
defect
pylor
stenosi
malform
bahat
dinur
lin
malm
cooper
louik
summari
experi
argu
increas
embryoand
fetotox
risk
erythromycin
sever
report
matern
hepatotox
chang
erythromycin
estol
administ
second
half
pregnanc
women
develop
cholestat
icteru
second
week
treatment
abat
within
week
treatment
discontinu
without
evid
perman
damag
sign
fetal
compromis
eg
mccormack
azithromycin
clarithromycin
roxithromycin
also
studi
sever
public
without
indic
embryoor
fetotox
effect
baroz
baroz
chun
sarkar
drinkard
einarson
case
clarithromycin
antiinfect
agent
pregnanc
initi
concern
anim
experi
demonstr
teratogen
effect
instanc
studi
cardiovascular
defect
induc
rat
recent
danish
cohort
studi
base
prescript
regist
observ
increas
risk
miscarriag
clarithromycin
earli
pregnanc
increas
risk
major
malform
andersen
experi
dirithromycin
josamycin
midecamycin
spiramycin
troleandomycin
limit
czeizel
spiramycin
use
mani
first
trimest
treatment
toxoplamosi
although
report
focu
possibl
teratogen
effect
numer
normal
birth
spiramycin
exposur
reassur
publish
experi
use
ketolid
telithromycin
first
trimest
anim
experi
show
agent
teratogen
local
treatment
macrolid
quit
safe
fetu
yet
resist
develop
quickli
allergi
frequent
macrolid
use
reserv
clindamycin
lincomycin
belong
lincosamid
group
inhibit
bacteri
protein
synthesi
bactericid
bacteriostat
depend
concentr
sensit
oral
dose
resorpt
almost
complet
half
matern
concentr
attain
umbil
vein
sign
embryoor
fetotox
effect
sever
hundr
pregnant
women
treat
lincomycin
differ
point
pregnanc
czeizel
mickal
also
problem
found
clindamycin
pseudomembran
enterocol
danger
matern
complic
clindamycin
treatment
may
also
happen
vagin
applic
pregnanc
complic
due
bacteri
vaginosi
suffici
prevent
vagin
clindamycin
therapi
joesoef
note
though
investig
found
reduct
late
abort
prematur
treat
sever
hundr
patient
oral
clindamycin
abnorm
vagin
flora
ugwumadu
recommend
erythromycin
clarithromycin
azithromycin
roxithromycin
may
use
pregnanc
resist
spectrum
requir
case
allergi
penicillin
hepatotox
erythomycin
estol
given
second
third
trimest
spiramycin
treatment
choic
toxoplasmosi
first
trimest
telithromycin
makrolid
given
pregnanc
altern
avail
recommend
clindamycin
lincomycin
use
penicillin
cephalosporin
macrolid
fail
clindamycin
routin
use
dental
procedur
bacteriostat
effect
tetracyclin
base
inhibit
bacteri
protein
synthesi
broadspectrum
antibiot
especi
tetracyclin
form
stabl
chelat
calcium
ion
standard
agent
today
doxycyclin
minocyclin
especi
lipophil
display
somewhat
wider
antibacteri
spectrum
doxycyclin
older
deriv
oxytetracyclin
tetracyclin
rare
use
poorli
resorb
chlortetracyclin
demeclocyclin
meclocyclin
use
local
agent
tigecyclin
minocyclin
deriv
belong
glycylcyclin
broadspectrum
especi
effect
multiresist
pathogen
mrsa
tetracyclin
cross
placenta
accord
current
knowledg
increas
risk
malform
expect
tetracyclin
use
cooper
czeizel
result
populationbas
casecontrol
studi
suggest
oxytetracyclin
associ
increas
incid
congenit
malform
czeizel
howev
number
case
studi
small
studi
confirm
suspicion
danish
cohort
studi
found
associ
oral
cleft
matern
tetracyclin
exposur
second
month
result
base
two
expos
case
sixteenth
week
pregnanc
fetal
miner
take
place
tetracyclin
bind
calcium
ion
develop
teeth
bone
numer
public
describ
brownyellow
discolor
teeth
children
prenat
expos
tetracyclin
dental
discolor
proven
prenat
side
effect
tetracyclin
human
discuss
also
enamel
defect
lead
increas
risk
cari
inhibit
growth
long
bone
specif
fibula
cataract
due
deposit
len
doxycyclin
weaker
affin
calcium
ion
older
tetracyclin
risk
appear
lower
doxycyclin
exposur
discolor
milk
teeth
expect
prior
sixteenth
week
gestat
even
thereaft
worst
first
molar
perman
teeth
would
affect
usual
therapeut
regimen
current
dose
adher
bigger
risk
describ
develop
abnorm
possibl
expect
higher
tetracyclin
dose
second
third
trimest
necessari
exampl
malaria
treatment
past
use
tetracyclin
especi
high
dose
via
intraven
administr
second
half
pregnanc
associ
sever
matern
hepat
toxic
eg
lewi
case
patient
kidney
problem
whose
serum
concentr
markedli
therapeut
rang
untoward
effect
describ
pregnant
women
appli
tetracyclin
local
pregnanc
lack
experi
tigecyclin
statement
made
toler
pregnanc
local
applic
silver
sulfadiazin
use
burn
injuri
sulfacetamid
eye
infect
sulfonamid
attain
matern
concentr
fetu
compet
bilirubin
bind
site
albumin
today
sulfonamid
seldom
use
monotherapi
spectrum
limit
resist
develop
rapidli
combin
folat
antagonist
trimethoprim
pyrimethamin
section
sulfonamid
indic
among
other
treatment
toxoplasmosi
malaria
fix
combin
sulfonamid
sulfamethoxazol
trimethoprim
avail
cotrimoxazol
agent
combin
subject
pregnancyinduc
variat
clearanc
would
requir
dose
modif
trimethoprim
effect
monotherapi
uncompl
urinari
tract
infect
sensit
pathogen
date
indic
sulfonamid
trimethoprim
combin
teratogen
potenti
human
czeizel
embryotox
potenti
discuss
time
time
antagonist
folic
acid
lead
malform
anim
experi
human
spontan
incid
neural
tube
defect
spina
bifida
decreas
administr
folic
acid
earli
pregnanc
chapter
fact
human
folic
acid
reductas
much
less
sensit
trimethoprim
bacteri
enzym
could
explain
teratogen
problem
far
document
human
antibiot
folic
acid
antagonist
use
trimethoprim
use
mani
decad
pregnant
women
present
ongo
discuss
concern
associ
use
folic
acid
antagonist
increas
risk
congenit
malform
retrospect
casecontrol
studi
discuss
causal
relationship
treatment
trimethoprim
folic
acid
antagonist
develop
neural
tube
defect
cardiovascular
abnorm
cleft
lip
palat
urinari
tract
anomali
hernandezdiaz
author
view
prevent
dose
multivitamin
folic
acid
prepar
vari
addit
casecontrol
studi
notabl
methodolog
problem
found
weakli
recommend
tetracyclin
contraind
fifteenth
gestat
week
prior
antibiot
second
choic
doxycyclin
prefer
case
inadvert
use
tetracyclin
even
fifteenth
week
indic
termin
pregnanc
chapter
realli
necessari
local
applic
small
area
may
conduct
throughout
pregnanc
tigecyclin
reserv
special
situat
suffici
test
antibiot
effect
signific
evid
develop
cardiovascular
defect
urinari
tract
anomali
anencephali
limb
defect
orofaci
cleft
eg
crider
czeizel
increas
risk
preterm
birth
low
birth
weight
also
observ
exposur
trimethoprimsulfamethoxazol
santo
yang
danish
cohort
studi
base
prescript
regist
found
doubl
hazard
miscarriag
trimethoprim
exposur
first
trimest
andersen
base
prescript
regist
increas
risk
heart
limb
defect
observ
preconcept
exposur
week
concept
trimethoprim
andersen
besid
methodolog
problem
associ
seem
unlik
shortterm
therapi
trimethoprim
usual
lead
relev
folic
acid
defici
possibl
caus
birth
defect
trimethoprim
sulfonamid
drug
first
choic
exhibit
establish
teratogen
accord
current
knowledg
teratogen
risk
trimethoprim
sulfonamid
therapi
neglig
actual
suffici
convinc
argument
support
recommend
addit
folic
acid
administr
antibiot
therapi
discuss
medic
see
chapter
addit
discuss
concern
folic
acid
usag
extens
gener
reassur
experi
use
cotrimoxazol
common
urinari
tract
infect
pregnanc
includ
conclus
medic
safe
use
much
higher
dose
opportunist
infect
pneumocysti
pneumonia
context
hiv
infect
far
report
malform
therapi
use
pregnant
women
systemat
studi
local
applic
sulfonamid
pregnanc
sulfonamid
compet
bilirubin
bind
site
plasma
protein
argu
risk
neonat
kernicteru
increas
sulfonamid
given
end
gestat
current
surveil
danger
kernicteru
tangibl
howev
rise
bilirubin
especi
prematur
infant
exclud
sulfonamid
use
birth
danish
populationbas
studi
could
find
associ
sulfamethoxzol
exposur
near
term
increas
risk
neonat
jaundic
klarskov
quinolon
inhibit
bacteri
enzym
topoisomeras
ii
iv
import
nucleic
acid
metabol
bacteria
quinolon
recommend
sulfonamid
trimethoprim
cotrimoxazol
antibiot
second
choic
throughout
pregnanc
high
dose
cotrimoxazol
use
pneumocysti
pneumonia
first
trimest
base
theoret
ground
folic
acid
supplement
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
prematur
birth
threaten
sulfonamid
avoid
view
bilirubin
level
newborn
shortterm
local
treatment
accept
especi
site
small
high
affin
cartilag
bone
tissu
highest
immatur
cartilag
pipemid
acid
nalidixid
acid
belong
group
older
quinolon
displac
newer
fluoroquinolon
import
fluoroquinolon
includ
ciprofloxacin
enoxacin
levofloxacin
moxifloxacin
norfloxacin
ofloxacin
sever
substanc
remov
market
sever
side
effect
garenoxacin
lomefloxacin
pefloxacin
rosoxacin
sparfloxacin
still
avail
countri
gatifloxacin
nadifloxacin
use
local
agent
quinolon
cross
placenta
found
amniot
fluid
low
concentrationswhen
moxifloxacin
use
matern
serum
concentr
measur
amniot
fluid
lovofloxacin
quinolon
found
teratogen
anim
sever
irrevers
damag
joint
cartilag
note
young
dog
treat
birth
quinolon
eg
gough
alter
describ
prenat
expos
children
mani
public
fail
show
indic
joint
cartilag
damag
increas
risk
malform
baroz
cooper
larsen
loebstein
schaefer
berkovitch
one
studi
express
concern
prenat
use
fluoroquinolon
may
associ
increas
risk
bone
malform
wogeliu
although
resembl
three
four
birth
defect
skeleton
affect
howev
studi
women
redeem
prescript
fluoroquinolon
first
trimest
day
concept
total
malform
rate
increas
wogeliu
prospect
cohort
studi
women
expos
fluorquinolon
first
trimest
neither
rate
major
birth
defect
risk
spontan
abort
increas
compar
control
group
padberg
altogeth
data
avail
norfloxacin
ciprofloxacin
lesser
extent
levofloxacin
moxifloxacin
ofloxacin
pefloxacin
data
fluoroquinolon
report
undesir
side
effect
topic
use
quinolon
pregnanc
nitrofurantoin
chemotherapeut
agent
drugresist
urinari
tract
infect
uti
prevent
recurr
uti
act
bacteriostat
also
bactericid
higher
concentr
detail
mechan
action
remain
clarifi
oral
dose
therapeut
effect
level
attain
urinari
tract
sever
public
support
associ
nitrofurantoin
congenit
malform
nordeng
goldberg
quinolon
antibiot
second
choic
pregnanc
wellfound
situat
better
studi
antibiot
ineffect
quinolon
well
document
may
prefer
norfloxacin
ciprofloxacin
detail
ultrasound
examin
may
offer
exposur
fluoroquinolon
first
trimest
local
treatment
quinolon
accept
throughout
pregnanc
czeizel
ben
david
although
number
studi
methodolog
fault
weakli
signific
find
note
craniosysnostosi
ophthalm
malform
oral
cleft
cardiovascular
defect
crider
casecontrol
studi
observ
increas
risk
craniosynostosi
intrauterin
exposur
nitrosat
drug
gardner
nitrofurantoin
lower
activ
glutathion
reductas
discuss
aris
period
whether
intrauterin
exposur
could
trigger
fetal
hemolysi
bruel
report
matur
newborn
hemolyt
anemia
whose
mother
took
nitrofurantoin
last
gestat
month
nitrofurantoin
often
use
pregnanc
fetal
hemolysi
commonli
observ
therefor
relev
risk
like
howev
nordeng
observ
increas
risk
neonat
jaundic
matern
nitofurantoin
treatment
last
day
deliveri
case
report
pregnant
woman
develop
toxic
hepat
expos
nitrofurantoin
thirtysixth
week
aksamija
anoth
case
woman
took
nitrofurantoin
thirtythird
week
interpret
present
gestat
nitrofurantoininduc
pneumonia
moham
nitrofurantoin
deriv
nifuroxazid
use
treatment
diarrhea
document
report
toler
pregnanc
evid
effect
nifurtimox
nitrofuran
use
treatment
chaga
diseas
experi
pregnanc
limit
world
health
organ
recommend
nifurtimox
taken
pregnant
women
one
studi
safeti
includ
pregnant
women
give
inform
pregnanc
outcom
schmid
local
treatment
nitrofuran
furazolidon
nitrofur
nifuratel
avail
evid
embryoor
fetotox
risk
local
applic
use
local
nitrofuran
especi
vagin
therapi
remain
controversi
need
critic
assess
pregnanc
methenamin
uti
medic
releas
antisept
formaldehyd
urin
methenamin
mandel
use
chronic
uti
due
e
coli
unproblemat
germ
effect
toler
agent
remain
controversi
embryoor
fetotox
problem
report
report
use
hydroxyquinolon
deriv
nitroxolin
pregnanc
fosfomycin
broadspectrum
antibiot
bactericid
inhibit
synthesi
bacteri
cell
wall
use
intraven
inject
reserv
antibiot
sever
infect
osteomyel
fosfomycin
tromethamin
oral
taken
salt
fosfomycin
use
treatment
uncompl
uti
author
also
recommend
oral
use
pregnanc
eg
falaga
bayrak
studi
howev
primarili
focus
effect
fosfomycin
tromethamin
risk
newborn
overal
experi
argu
teratogen
fetotox
potenti
human
nitroimidazol
effect
bactericid
agent
anaerob
protozoa
convert
metabolit
imped
intracellular
bacteri
dna
synthesi
main
repres
nitroimidazol
metronidazol
metronidazol
recommend
investig
treatment
bacteri
vaginosi
pregnanc
high
risk
preterm
deliveri
strategi
decreas
risk
review
joesoef
other
howev
fail
notic
improv
incid
prematur
shennan
andrew
klebanoff
oral
intraven
administr
concentr
high
mother
reach
embryofetu
signific
system
absorpt
occur
vagin
applic
expos
fetu
well
pharmacokinet
profil
metronidazol
chang
differ
time
point
assess
pregnanc
differ
nonpregn
patient
wang
like
nitroimidazol
metronidazol
display
experiment
mutagen
cancerogen
potenti
review
dobia
confirm
human
investig
rang
year
show
indic
increas
risk
cancer
metronidazol
use
beard
basi
analyz
pregnanc
state
metronidazol
teratogen
potenti
human
eg
koss
diavcitrin
czeizel
suggest
hungarian
malform
registri
link
vagin
therapi
metronidazol
miconazol
second
third
month
increas
appear
syndactyli
hexadactyli
confirm
investig
kazi
nimorazol
tinidazol
regist
treatment
trichomona
infect
amebiasi
bacteri
vaginosi
evalu
suffici
lack
human
data
appli
ornidazol
far
report
human
teratogen
aminoglycosid
antibiot
amikacin
framycetin
gentamicin
kanamycin
neomycin
netilmicin
paromomycin
ribostamycin
streptomycin
recommend
nitrofurantoin
given
pregnanc
treat
urinari
tract
infect
antibiot
choic
ineffect
possibl
avoid
toward
end
pregnanc
use
nifuroxazid
nifurtimox
local
nitrofuran
methenamin
nitroxolin
avoid
pregnanc
antibiot
choic
pregnanc
use
fosfomycin
tromethamin
may
use
treat
urinari
tract
infect
pregnanc
intraven
applic
fosfomycin
restrict
sever
bacteri
infect
problemat
germ
recommend
metronidazol
may
use
pregnanc
indic
singl
oral
dose
g
prefer
vagin
administr
spread
sever
day
particularli
doubt
effect
vagin
applic
parenter
administr
indic
seriou
anaerob
infect
metronidazol
prefer
less
examin
nitroimidazol
tobramycin
inhibit
protein
synthesi
bactericid
primarili
gramneg
germ
oral
administr
minim
portion
aminoglycosid
resorb
parenter
administr
matern
plasma
concentr
detect
fetu
spectinomycin
aminocyclitol
antibiot
close
relat
aminoglycosid
otoand
nephrotox
side
effect
also
known
occur
nonpregn
patient
aminolgycosid
use
parenter
case
report
parenter
use
kanamycin
streptomycin
pregnanc
describ
auditori
problem
even
deaf
children
expos
utero
eg
jone
conway
robinson
similar
case
report
connect
gentamicin
investig
hear
abil
children
whose
mother
receiv
gentamicin
intraven
pregnanc
found
defici
argu
major
ototox
risk
gentamicin
use
pregnanc
kirkwood
theoret
fetal
nephrotox
risk
exist
aminoglycosid
concentr
fetal
kidney
case
report
connat
kidney
dysplasia
matern
gentamicin
therapi
hulton
prove
clinic
relev
human
risk
case
hydronephrosi
suspect
stenosi
uteropelv
junction
lethal
outcom
mother
treat
uti
first
ciprofloxacin
gentamicin
week
yari
except
case
report
studi
argu
high
otoor
nephrotox
risk
gentamicin
fetu
newborn
increas
observ
malform
czeizel
untoward
effect
describ
aminoglycosid
local
treatment
pregnanc
experi
spectinomycin
insuffici
analyz
risk
pregnanc
glycopeptid
polypeptid
antibiot
glycopeptid
antibiot
glycopeptid
vancomycin
teicoplanin
bactericid
gramposit
pathogen
inhibit
cell
wall
synthesi
consid
reserv
antibiot
use
msra
multiresist
enterococci
avoid
develop
resist
applic
critic
apprais
possibl
limit
fight
problemat
pathogen
oral
glycopeptid
hardli
resorb
use
treat
pseudomembran
enterocol
vancomycin
howev
situat
metronidazol
section
consid
altern
vancomycin
therapi
expens
prevent
select
vancomycinresist
enterococci
vancomycin
cross
placenta
reach
fetu
relev
quantiti
laiprasert
shown
teratogen
effect
anim
studi
experi
treatment
human
pregnanc
limit
recommend
aminoglycosid
use
parenter
lifethreaten
infect
difficult
gramneg
pathogen
firstchoic
antibiot
fail
serum
level
need
monitor
regularli
treatment
riskbas
termin
pregnanc
invas
diagnost
requir
chapter
parenter
therapi
extens
renal
function
monitor
neonat
auditori
test
perform
local
oral
applic
aminoglycosid
indic
given
system
absorpt
minim
rout
pregnanc
case
report
observ
malform
kidney
damag
hear
deficit
rey
experi
teicoplanin
new
lipoglycopeptid
dalbavancin
oritavancin
telavancin
insuffici
analyz
risk
pregnanc
vitro
telavancin
cross
human
placenta
fetal
concentr
reach
less
matern
concentr
nanovskaya
daptomycin
belong
new
class
cyclic
lipopeptid
effect
exclus
gramposit
bacteria
work
interf
bacteri
cell
membran
protein
synthesi
indic
treat
complic
infect
difficult
pathogen
anim
experi
daptomycin
cross
placenta
teratogen
two
children
whose
mother
took
daptomycin
fourteenth
twentyseventh
week
unremark
stroup
shea
polymyxin
belong
polypeptid
antibiot
bactericid
interf
transport
mechan
cell
wall
polymyxin
colistin
today
mostli
use
local
also
appli
parenter
infect
multiresist
gramneg
germ
patient
mucoviscidosi
use
inhal
enter
colistin
resorb
therefor
oral
administr
use
select
decontamin
intestin
tract
polypeptid
antibiot
bacitracin
polymyxin
b
tyrothricin
use
local
limit
experi
avail
applic
polypeptid
antibiot
pregnanc
indic
substanti
risk
kazi
antibiot
chloramphenicol
tiamphenicol
inhibit
bacteri
protein
synthesi
bacteriostat
activ
chloramphenicol
rel
toxic
caus
sever
agranulocytosi
cross
placenta
well
reach
therapeut
concentr
fetu
prematur
term
birth
may
lead
grey
babi
syndrom
chloramphenicol
reach
toxic
level
neonat
even
mother
treat
suggest
malform
czeizel
recommend
glycopeptid
use
case
lifethreaten
bacteri
infect
vancomycin
prefer
recommend
use
daptomycin
limit
case
lifethreaten
bacteri
infect
recommend
parent
use
colistin
limit
case
lifethreaten
bacteri
infect
local
oral
applic
polypeptid
antibiot
need
critic
assess
experi
thiamphenicol
insuffici
analyz
risk
pregnanc
dapson
use
among
indic
leprosi
appar
teratogen
potenti
eg
lush
bhargava
howev
case
hemolyt
anemia
report
mother
newborn
dapson
bear
structur
similar
sulfonamid
argu
might
compet
bilirubin
protein
bind
thu
could
lead
hyperbilirubinemia
newborn
fidaxomicin
macrocycl
antibiot
approv
treatment
infect
clostridium
difficil
enter
fidaxomicin
poorli
resorb
experi
report
use
pregnanc
linezolid
member
oxazolidinon
class
new
group
antibiot
act
bactericid
inhibit
bacteri
protein
synthesi
indic
treatment
multiresist
pathogen
one
case
report
use
linezolid
pregnanc
intrauterin
exposur
gestat
week
healthi
infant
deliv
term
mercieri
antiprotozo
agent
pentamidin
among
other
effect
pneumocysti
pneumonia
evalu
suffici
pregnanc
recommend
system
use
chloramphenicol
thiamphenicol
contraind
throughout
pregnanc
except
lifethreaten
matern
infect
respond
less
toxic
antibiot
system
treatment
absolut
necessari
birth
import
observ
newborn
toxic
symptom
local
applic
also
avoid
pregnanc
recommend
pregnanc
dapson
reserv
specif
indic
treatment
took
place
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
recommend
fidaxomicin
avoid
pregnanc
treatment
took
place
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
recommend
lack
experi
linezolid
use
sever
infect
problemat
germ
treatment
took
place
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
pregnanc
estim
embryotox
potenti
human
usual
replac
antibiot
eg
cotrimoxazol
section
rifaximin
antibiot
treat
travel
diarrhea
enough
experi
regard
use
pregnanc
minim
enter
resorpt
neg
anim
test
suggest
high
embryotox
risk
unlik
streptogramin
group
cyclic
peptid
antibiot
inhibit
like
macrolid
lincosamid
synthesi
bacteri
protein
deriv
natur
occur
pristinamycin
later
develop
deriv
quinupristin
dalfopristin
use
fix
combin
streptogramin
appli
reserv
antibiot
infect
highli
resist
gramposit
germ
report
use
pregnanc
avail
activ
tuberculosi
tb
requir
treatment
pregnanc
diseas
endang
mother
also
fetu
pregnanc
seem
affect
cours
tb
preval
congenit
tb
less
treatment
initi
lin
investig
newborn
mother
receiv
treatment
tb
gestat
children
smaller
lower
birth
weight
control
group
children
healthi
mother
slight
differ
recommend
differ
organ
world
intern
union
tuberculosi
lung
diseas
iuatld
sever
nation
organ
eg
blumberg
treatment
consider
depend
diseas
statu
drug
resist
firstlin
drug
treatment
tb
pregnanc
isoniazid
pyridoxin
rifampicin
ethambutol
pyrazinamid
standard
medic
shown
teratogen
fetotox
effect
human
eg
bothamley
far
know
today
tb
drug
reach
fetu
relev
quantiti
increas
develop
resist
make
harder
choos
right
medic
pregnanc
pregnant
women
multidrugresist
tb
mdrtb
may
also
requir
secondlin
antitubercul
recommend
pentamidin
reserv
pregnanc
special
situat
better
test
antibiot
effect
treatment
took
place
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
recommend
possibl
rifaximin
avoid
pregnanc
recommend
streptogramin
avoid
pregnanc
treatment
took
place
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
drug
necess
treatment
weigh
risk
fetu
individu
base
current
experi
manag
mdrtb
argu
high
risk
reserv
drug
newborn
drobac
shin
streptomycin
howev
avoid
ototox
potenti
ethambutol
bacteriostat
drug
use
tuberculosi
cross
placenta
risk
congenit
malform
use
pregnanc
appear
low
report
indic
ethambutol
caus
ocular
toxic
fetu
adult
given
higher
dose
isoniazid
inh
proven
highli
effect
drug
mani
strain
mycobacterium
use
tubercul
prophylaxi
treatment
activ
diseas
pregnanc
although
inh
cross
placenta
appear
teratogen
even
given
first
trimest
older
literatur
contain
case
report
differ
malform
neurolog
damag
prenat
expos
children
inh
intak
lack
pyridoxin
comed
even
tb
diseas
blame
newer
public
confirm
teratogen
risk
eg
taylor
summari
experi
speak
major
risk
inh
increas
pyridoxin
metabol
may
respons
cn
toxic
prevent
possibl
vitamin
defici
inh
given
pregnanc
combin
pyridoxin
pyrazinamid
pza
antibiot
specif
effect
mycobacterium
tuberculosi
structur
resembl
nicotinamid
assum
interven
nucleic
acid
metabol
bacteri
cell
pza
effect
bactericid
properti
systemat
studi
toler
pregnanc
lack
far
evid
embryoor
fetotox
effect
human
use
pza
pregnanc
recommend
sever
guidelin
eg
american
thorac
societi
recommend
guidelin
hold
pza
reserv
drug
pregnanc
current
insuffici
data
teratogen
blumberg
pza
use
treatment
may
prolong
recommend
ethambutol
firstlin
drug
treatment
tuberculosi
pregnanc
recommend
isoniazid
firstlin
drug
treatment
tuberculosi
pregnanc
need
given
togeth
pyridoxin
rifampicin
also
call
rifampin
inhibit
bacteri
rna
polymeras
effect
bactericid
agent
differ
pathogen
particularli
mycobacteria
rifampicin
cross
placenta
anim
experi
teratogen
effect
seen
dose
time
higher
human
treatment
rifampicin
inhibit
dnadepend
rna
polymeras
concern
might
interfer
fetal
develop
report
literatur
confirm
fear
appar
increas
risk
malform
longterm
therapi
mother
could
result
inhibit
vitamin
k
synthesi
result
higher
bleed
tendenc
neonat
streptomycin
aminoglycosid
use
parenter
treatment
tb
bactericid
particularli
affect
germ
prolifer
extracellularli
ototox
also
hurt
fetu
section
asid
discuss
firstlin
drug
tb
reserv
medic
avail
use
case
resist
intoler
systemat
studi
exist
toler
acid
paminosalicyl
acid
pa
far
evid
embryoor
fetotox
effect
found
human
eg
low
capreomycin
ethionamid
protionamid
rifabutin
rifapentin
thioacetazon
terizidon
prodrug
cycloserin
secondlin
agent
use
intern
mdrtb
extent
document
experi
pregnanc
limit
insuffici
differenti
risk
assess
singl
case
report
argu
high
teratogen
risk
drug
eg
lessnau
drobac
addit
reserv
drug
multiresist
tb
amikacin
see
section
divers
quinolon
see
section
antiinfect
agent
view
relev
section
chapter
recommend
pyrazinamid
may
use
pregnanc
treat
activ
tb
recommend
rifampicin
firstlin
drug
treatment
tuberculosi
pregnanc
use
near
term
newborn
receiv
extend
vitamin
k
prophylaxi
chapter
regard
infect
mrsa
rifampicin
administ
drug
first
choic
pregnanc
use
recommend
streptomycin
contraind
pregnanc
ototox
properti
inadvert
exposur
requir
riskbas
termin
pregnanc
invas
diagnost
procedur
hear
test
perform
birth
chapter
gener
extern
antibiot
treatment
need
examin
care
see
whether
bacteri
infect
effect
treat
system
medic
potenti
local
treatment
often
overestim
topic
therapi
sensit
resist
develop
need
consid
fusafungin
bacteriostat
antiinflammatori
effect
use
spray
treatment
infect
nose
throat
area
insuffici
experi
applic
pregnanc
fusid
acid
antibiot
almost
exclus
use
extern
prenat
toler
examin
systemat
although
medic
avail
long
time
narrow
spectrum
effect
gramposit
bacteria
staphylococci
recommend
untarget
treatment
mupirocin
primarili
bacteriostat
affect
staphylococci
streptococci
inhibit
bacteri
protein
synthesi
especi
use
nasal
ointment
elimin
mrsa
mupirocin
examin
systemat
evid
undesir
effect
pregnanc
retapamulin
first
repres
pleuromutilin
approv
human
treatment
appli
ointment
shortterm
treatment
superfici
skin
infect
retapamulin
inhibit
bacteri
protein
synthesi
bacteriostat
primarili
gramposit
germ
system
resorpt
minim
topic
use
nevertheless
experi
pregnanc
limit
applic
need
critic
examin
taurolidin
antimicrobi
solut
use
lavag
periton
prevent
infect
cathet
bactericid
agent
mechan
action
partial
clarifi
report
experi
pregnanc
see
correspond
section
local
applic
aminoglycosid
section
chloramphenicol
section
quinolon
section
macrolid
section
nitrofuran
section
nitroimidazol
section
polypeptid
antibiot
section
sulfonamid
section
tetracyclin
section
apart
pregnant
women
live
malaria
area
pregnant
women
increasingli
travel
tropic
countri
need
suitabl
malaria
prophylaxi
increas
resist
malaria
pathogen
make
difficult
suggest
gener
recommend
guidelin
tropic
medicin
recommend
reserv
drug
discuss
use
multiresist
tuberculosi
standard
therapi
indic
inadvert
exposur
pregnanc
requir
riskbas
termin
invas
diagnost
detail
ultrasound
examin
carri
chapter
recommend
extern
use
antibiot
suspect
teratogen
nevertheless
applic
local
antibiot
need
critic
assess
antibiot
safe
use
system
may
also
use
local
anoth
local
antibiot
absolut
necessari
may
use
pregnanc
follow
also
pregnanc
accord
travel
destin
especi
difficult
manag
malaria
tropica
caus
plasmodium
falciparum
pregnanc
enhanc
clinic
sever
falciparum
malaria
especi
primipar
nonimmun
woman
pregnanc
alter
woman
immun
malaria
make
suscept
malaria
infect
increas
risk
ill
sever
anaemia
death
matern
malaria
increas
risk
spontan
abort
stillbirth
prematur
low
birth
weight
thu
result
excess
infant
mortal
eg
bardaji
shulman
therefor
mosquitobit
prevent
prophylaxi
treatment
malaria
shorten
omit
ongo
pregnanc
travel
area
multidrugresist
malaria
avoid
possibl
choic
drug
malaria
prophylaxi
treatment
pregnanc
depend
local
pattern
antimalari
drug
resist
sever
malaria
degre
preexist
immun
import
well
inform
current
recommend
prophylaxi
treatment
malaria
area
visit
travel
malariaendem
area
gener
recommend
difficult
increas
resist
depend
drug
chemoprophylaxi
must
continu
week
leav
malari
region
women
live
falciparumendem
area
stabl
transmiss
world
health
organ
recommend
use
insecticidetr
net
itn
intermitt
prevent
treatment
ipt
sulfadoxinepyrimethamin
pregnanc
nyunt
ipt
reduc
matern
malaria
episod
matern
anaemia
placent
parasitaemia
low
birth
weight
neonat
mortal
review
mcclure
prompt
diagnosi
effect
treatment
malaria
infect
vital
although
data
prospect
studi
limit
quinin
chloroquin
proguanil
clindamycin
section
consid
safe
earli
pregnanc
pregnant
women
first
trimest
uncompl
malaria
tropica
treat
quinin
plu
clindamycin
avail
second
third
trimest
world
health
organ
recommend
artemisinin
deriv
choic
combin
partner
difficult
limit
inform
reserv
medic
includ
follow
amodiaquin
atovaquon
dapson
section
lumefantrin
mefloquin
piperaquin
pyrimethamin
plu
sulfadoxin
doxycyclin
contraind
sixteenth
gestat
week
section
halofantrin
primaquin
avoid
see
relev
section
chapter
specif
activ
substrat
gestat
plasma
concentr
mani
antimalaria
agent
lower
elimin
enhanc
result
treatment
failur
thu
patient
dose
dose
interv
need
assess
individu
recommend
gener
physician
discuss
patient
trip
tropic
region
could
postpon
section
risk
exposur
reduc
long
cloth
mosquito
net
repel
case
medic
deni
prophylaxi
treatment
behalf
pregnanc
potenti
risk
unborn
child
predomin
medic
inadequ
pregnanc
experi
use
first
trimest
detail
ultrasound
examin
offer
riskbas
termin
justifi
abovedescrib
medic
use
pregnanc
chapter
amodiaquin
like
chloroquin
belong
group
caus
sever
side
effect
liver
damag
agranulocytosi
reason
unsuit
prophylaxi
use
limit
reserv
medic
malaria
evid
tetatogen
review
thoma
experi
limit
regard
earli
pregnanc
singl
case
report
publish
one
studi
found
mild
matern
side
effect
pregnant
women
treat
second
third
trimest
increas
miscarriag
prematur
stillbirth
malform
observ
tagbor
artemisinin
deriv
artemeth
artemotil
artesun
dihydroartemisinin
increasingli
use
malaria
plasmodium
falciparum
develop
resist
drug
compound
combin
rapid
blood
schizonticid
activ
wide
therapeut
index
artemisinin
given
combin
therapi
protect
resist
typic
combin
artemisininbas
combin
therapi
act
artemeth
plu
lumefantrin
artesun
plu
amodiaquin
artesun
plu
mefloquin
artesun
plu
sulfadoxinepyrimethamin
dihydroartemisinin
plu
piperaquin
first
trimest
experi
use
artemisinin
deriv
limit
number
studi
contain
data
pregnant
women
treat
artemisinin
deriv
first
trimest
without
show
evid
teratogen
risk
mosha
adam
clark
manyando
commonli
found
umbil
hernia
addit
children
whose
mother
treat
artemeth
lumefantrin
month
hernia
detect
anymor
experi
pregnant
women
use
artemisinin
deriv
second
third
trimest
eg
piola
bounyasong
deen
mcgreadi
phillipshoward
summari
studi
find
increas
risk
miscarriag
stillbirth
malform
degre
artemisisin
deriv
better
toler
pregnant
women
effect
treatment
control
group
plasma
level
artemeth
decreas
pregnanc
suggest
dose
dose
interv
may
adjust
eg
tarn
morri
reassur
data
led
recommend
use
artemisinin
deriv
medic
choic
malaria
tropica
second
third
trimest
specifi
combin
recommend
context
act
first
trimest
base
lack
experi
view
artemisinin
deriv
reserv
medic
withheld
individu
case
need
recommend
amodiaquin
may
use
reserv
medic
treatment
malaria
atovaquon
broadspectrum
antiprotozo
drug
also
use
pneumocysti
pneumonia
monotherapi
quickli
lead
resist
thu
combin
proguanil
use
malaria
prophylaxi
treatment
experi
atovaquon
limit
pregnanc
danish
cohort
studi
base
prescript
regist
women
expos
first
trimest
atovaquon
expos
time
week
concept
found
increas
risk
birth
defect
pasternak
use
second
third
trimest
small
studi
observ
advers
effect
mcgreadi
nabangchang
avail
data
insuffici
differenti
risk
assess
suggest
teratogen
risk
mcgreadi
discuss
need
dose
adjust
clearanc
increas
level
decreas
pregnanc
chloroquin
antimalaria
drug
group
work
well
effect
schizonticid
drug
erythrocyt
form
type
plasmodia
today
though
almost
pathogen
potenti
lethal
malaria
tropica
becom
resist
rather
well
toler
mani
decad
use
medic
resist
also
note
plasmodium
vivax
pathogen
less
sever
malaria
tertiana
plasmodium
oval
plasmodium
malaria
still
remain
mainli
sensit
chloroquin
chloroquin
embryoand
fetotox
use
usual
dose
malaria
prophylaxi
threeday
treatment
typic
malaria
attack
mcgreadi
phillipshoward
current
evid
suggest
fetal
ocular
toxic
chloroquin
use
antimalarian
medic
pregnanc
review
osadchi
lee
examin
pregnant
women
nonpregn
control
find
chang
pharmacokinet
serum
level
chloroquin
antiinflammatori
properti
chloroquin
use
also
antirheumat
therapi
section
antirheumat
dose
chloroquin
higher
use
malaria
prevent
recommend
artemisinin
deriv
may
use
second
third
trimest
first
trimest
reserv
medic
treatment
malaria
recommend
atovaquon
may
use
reserv
medic
treatment
malaria
recommend
chloroquin
may
use
throughout
pregnanc
prophylaxi
treatment
malaria
chloroquin
resist
parasit
like
demonstr
drug
must
use
halofantrin
rapid
schizonticid
effect
upon
erythrocyt
form
plasmodia
resist
chloroquin
antimalari
halofantrin
prolong
qt
interv
ekg
becaus
provok
lifethreaten
cardiac
arrhythmia
patient
heart
diseas
conjunct
arrhythmogen
medic
halofantrin
longer
recommend
limit
experi
pregnanc
allow
differenti
risk
analysi
lumefantrin
belong
group
arylamin
alcohol
like
quinin
mefloquin
halofantrin
artemeth
plu
lumefantrin
current
popular
artemisininbas
combin
therapi
experi
avail
regard
applic
first
trimest
without
show
evid
teratogen
risk
eg
mosha
second
third
trimest
studi
sever
hundr
patient
report
indic
major
risk
piola
manyando
found
mild
increas
umbil
hernia
children
whose
mother
took
artemeth
lumefantrin
first
trimest
disappear
followup
examin
conduct
month
later
summari
current
experi
suggest
major
embryoor
fetotox
risk
lumefantrin
pregnanc
plasma
concentr
lower
elimin
enhanc
thu
increas
risk
treatment
failur
eg
tarn
mefloquin
display
effect
rapid
activ
erythrocyt
form
plasmodia
current
experi
treat
pregnant
women
sever
hundr
first
trimest
suggest
teratogen
fetotox
potenti
human
eg
schlagenhauf
bounyasong
mcgreadi
one
singl
studi
use
mefloquin
debat
find
increas
rate
stillbirth
studi
compar
pregnant
women
receiv
mefloquin
malaria
found
significantli
higher
rate
stillbirth
treat
quinin
antimalari
nosten
studi
howev
confirm
risk
mefloquin
establish
medic
pregnanc
time
recommend
halofantrin
use
case
acut
threaten
malaria
manag
better
test
less
toxic
drug
cardiac
problem
issu
antimalaria
medic
must
use
recommend
lumefantrin
may
use
reserv
medic
treatment
malaria
recommend
mefloquin
may
use
throughout
pregnanc
prophylaxi
treatment
malaria
resist
fix
oral
combin
bisquinolon
piperaquin
dihydroartemisinin
dhp
new
promis
artemisininbas
combin
therapi
mechan
action
piperaquin
unknown
indonesian
observ
studi
detect
higher
rate
abort
first
trimest
exposur
dihydroartemisininpiperaquin
poespoprodjo
observ
base
five
abort
among
eight
pregnanc
studi
found
lower
risk
perinat
mortal
dihydroartemisininpiperaquin
second
third
trimest
compar
quininebas
regimen
limit
experi
pregnanc
allow
differenti
risk
analysi
signific
pharmacokinet
differ
pregnant
nonpregn
women
report
two
small
studi
hoglund
primaquin
deriv
effect
intrahepat
perman
form
plasmodium
vivax
plasmodium
oval
use
complet
elimin
pathogen
combin
blood
schizontocid
erythrocyt
parasit
primaquin
use
pregnanc
potenti
risk
hemolyt
effect
fetu
yet
studi
permit
wellground
risk
assess
howev
substanti
evid
teratogen
potenti
human
phillipshoward
proguanil
older
medic
malaria
prophylaxi
belong
folic
acid
antagonist
experienc
renaiss
becom
use
face
increas
chloroquin
resist
often
appli
combin
synergist
atovaquon
evid
embryotox
potenti
human
eg
pasternak
mcgreadi
mcgreadi
discuss
need
adjust
dose
clearanc
increas
blood
level
decreas
pregnanc
pyrimethamin
inhibitor
folic
acid
synthesi
also
use
treatment
toxoplasmosi
pneumocysti
pneumonia
malaria
recommend
piperaquin
may
use
reserv
medic
treatment
malaria
recommend
primaquin
therapeut
option
pregnanc
prophylact
elimin
hepat
spore
usual
postpon
time
birth
recommend
proguanil
may
use
throughout
pregnanc
prophylaxi
treatment
malaria
provid
resist
treatment
appli
combin
anoth
folic
acid
antagonist
sulfadoxin
section
particular
combin
use
intermitt
prevent
treatment
ipt
pregnanc
howev
increas
resist
start
limit
effect
popular
combin
newman
anim
experi
indic
embryotox
effect
concern
rais
use
folic
acid
antagonist
earli
pregnanc
numer
investig
howev
demonstr
increas
malform
risk
human
eg
manyando
phillipshoward
studi
suggest
pregnanc
advers
alter
pharmacokinet
pyrimethamin
sulfadoxin
eg
karunajeewa
green
data
inconsist
gener
recommend
dose
adjust
pregnanc
difficult
sulfadoxinepyrimethamin
given
earli
pregnanc
supplement
folic
acid
tenth
week
recommend
mg
per
day
coadministr
high
dose
mg
daili
compromis
efficaci
sulfadoxinepyrimethamin
pregnanc
quinin
oldest
antimalari
agent
work
well
effect
schizonticid
drug
erythrocyt
form
plasmodium
speci
despit
rel
high
toxic
narrow
therapeut
rang
use
increasingli
treatment
chloroquineresist
malaria
combin
clindamycin
section
effect
increas
concentr
fetu
high
mother
potenti
toxic
case
report
observ
children
auditori
visual
defect
use
quinin
pregnanc
howev
case
consider
higher
dose
administ
current
use
evid
increas
risk
abort
preterm
deliveri
use
standard
dosag
quinin
treatment
acut
malaria
phillipshoward
find
confirm
studi
sever
hundr
pregnant
women
expos
first
trimest
increas
rate
spontan
abort
congenit
malform
stillbirth
low
birth
weight
found
eg
adam
mcgreadi
quinin
increas
secret
insulin
elbadawi
especi
last
part
pregnanc
sever
matern
hypoglycaemia
induc
quinin
therapi
due
risk
hypoglycemia
guidelin
prefer
use
artemisinin
combin
manag
malaria
tropica
second
trimest
studi
metabol
quinin
pregnant
nonpregn
women
fail
show
signific
pharmacokinet
differ
author
conclud
dose
adjust
necessari
pregnanc
abdelrahim
induct
contract
high
dose
quinin
exclud
recommend
pyrimethamin
combin
sulfadoxin
may
administ
treatment
malaria
toxoplasmosi
drug
choic
combin
longterm
sulfonamid
especi
first
trimest
pyrimethamin
given
earli
pregnanc
supplement
folic
acid
see
also
chapter
quinin
compon
analges
compound
certain
beverag
although
lower
appar
nonembryotox
dose
azol
antifung
azol
deriv
inhibit
ergosterol
biosynthesi
therebi
caus
disturb
permeabl
function
fungal
cell
membran
azol
antifung
includ
two
broad
class
imidazol
triazol
anim
experi
azol
antifung
cross
placenta
teratogen
high
dose
regard
use
triazol
deriv
fluconazol
pregnanc
report
three
children
two
sibl
craniofaci
skelet
cardiac
malform
similar
seen
anim
studi
pursley
mening
mother
use
high
dose
fluconazol
mg
daili
beyond
first
trimest
longterm
basi
addit
case
report
describ
two
birth
involv
craniofaci
limb
cardiac
defect
two
mother
use
fluconazol
lopezrangel
aleck
case
share
characterist
antleybixl
syndrom
howev
evid
increas
risk
malform
prospect
cohort
studi
women
expos
first
trimest
mastroiacovo
sever
studi
first
trimest
exposur
lowdosag
regimen
fluconazol
vagin
candidiasi
appear
caus
increas
risk
malform
eg
jick
campomori
inman
danish
cohort
studi
base
prescript
regist
also
could
find
increas
risk
birth
defect
first
trimest
exposur
sever
thousand
pregnant
women
extend
analysi
danish
data
observ
increas
risk
tetralog
fallot
base
seven
case
preval
compar
unexpos
pregnanc
ci
rate
major
birth
defect
increas
case
low
singl
dose
consist
mg
fluconazol
usual
use
vagin
yeast
infect
itraconazol
triazol
deriv
widespectrum
activ
evid
teratogen
prospect
studi
examin
sever
hundr
women
first
trimest
exposur
eg
de
santi
baroz
exposur
shortterm
danish
regist
analysi
find
increas
risk
birth
defect
among
women
first
trimest
prescript
itraconazol
recommend
despit
toxic
quinin
belong
drug
choic
deal
chloroquineresist
malaria
tropica
pregnanc
situat
potenti
risk
treatment
much
smaller
fetu
danger
sever
matern
diseas
attent
need
paid
possibl
matern
hypoglycemia
even
though
embryotox
effect
due
quinin
analges
compound
expect
agent
avoid
conform
good
therapeut
practic
hold
regular
excess
consumpt
quinin
drink
imidazol
deriv
ketoconazol
usual
avoid
system
use
poorli
toler
mani
suitabl
altern
ketoconazol
administ
occas
treatment
cush
syndrom
inhibit
steroid
synthesi
theoret
decreas
testosteron
synthesi
might
imped
sexual
develop
male
foetus
howev
describ
ketoconazol
use
sever
case
pregnanc
good
matern
fetal
outcom
eg
boronat
berwaert
amado
retrospect
studi
data
hungarian
malform
registri
base
expos
subject
show
evid
increas
risk
malform
system
use
ketoconazol
kazi
analysi
danish
regist
observ
significantli
increas
risk
birth
defect
among
pregnant
women
prescript
agent
first
trimest
posaconazol
voriconazol
use
aspergillosi
invas
mycos
inform
lack
use
pregnanc
one
publish
case
report
normal
child
born
voriconazol
treatment
mother
second
third
trimest
shoai
tehrani
multitud
poorli
resorb
topic
azol
deriv
avail
treatment
superfici
fungal
infect
drug
group
introduc
first
name
clotrimazol
miconazol
thoroughli
investig
use
pregnanc
regard
clotrimazol
extens
studi
treatment
vagin
yeast
infect
indic
embryotox
potenti
eg
czeizel
king
also
suggest
increas
miscarriag
czeizel
note
decreas
prematur
vaginosi
treat
local
clotrimazol
experi
sever
thousand
pregnant
women
avail
miconazol
eg
czeizel
mcnelli
suggest
hungarian
malform
registri
link
vagin
therapi
miconazol
plu
metronidazol
second
third
gestat
month
increas
syndactyli
hexadactyli
substanti
studi
kazi
isra
report
describ
two
case
sever
skeleton
anomali
use
bifonazol
reminisc
anomali
seen
system
use
fluconazol
first
case
bifonazol
taken
oral
week
second
case
mgd
vagin
throughout
pregnanc
clearli
higher
dose
recommend
linder
dose
level
reach
nomal
recommend
topic
applic
teratogen
risk
note
yet
systemat
studi
lack
ketoconazol
see
azol
antifung
system
use
recommend
system
treatment
azol
deriv
becom
absolut
necessari
fluconazol
itraconazol
prefer
bettertest
medic
possibl
treatment
start
first
trimest
inadvert
exposur
pregnanc
requir
riskbas
termin
invas
diagnost
detail
ultrasound
examin
carri
chapter
clearli
less
experi
collect
local
applic
butoconazol
croconazol
econazol
fenticonazol
isoconazol
omoconazol
oxiconazol
sertaconazol
sulconazol
terconazol
tioconazol
teratogen
effect
observ
king
confirm
vagin
econazol
treatment
studi
pregnant
patient
czeizel
amphotericin
b
broadspectrum
antifung
agent
polyen
group
bind
ergosterol
cell
membran
fungi
disturb
cell
wall
permeabl
use
intraven
oral
local
oral
applic
poorli
resorb
thu
local
effect
intestin
tract
convent
amphotericin
b
given
parenter
number
side
effect
primarili
nephrotox
newer
lipid
formul
amphotericin
b
liposom
amphotericin
b
character
markedli
better
toler
less
nephrotox
amphotericin
pass
placenta
relev
plasma
concentr
could
measur
newborn
although
mother
taken
last
dose
four
month
prior
dean
could
due
placent
accumul
delay
elimin
fetal
kidney
sever
case
report
indic
increas
risk
malform
amphotericin
b
eg
costa
eli
king
pregnanc
cours
liposom
amphotericin
b
also
argu
embryoor
fetotox
risk
eg
mueller
pagliano
pipiton
experi
insuffici
differenti
risk
assess
resorpt
minim
oral
local
use
risk
appear
unlik
echinocandin
new
antifung
medic
group
parenter
synthet
lipopeptid
inhibit
synthesi
key
ingredi
fungal
cell
wall
anidulafungin
caspofungin
micafungin
current
approv
anim
experi
echinocandin
cross
placenta
report
use
pregnanc
yalaz
describ
success
postnat
applic
caspofungin
dystroph
prematur
newborn
twenthseventh
gestat
week
recommend
clotrimazol
miconazol
belong
local
antifung
medic
choic
pregnanc
azol
deriv
antimycot
drug
second
choic
recommend
amphotericin
b
use
parenter
case
seriou
dissemin
fungal
infect
liposom
formul
may
prefer
treatment
took
place
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
oral
local
use
amphotericin
b
accept
pregnanc
flucytosin
effect
cryptococcu
neoforman
mani
candida
speci
inhibit
dna
synthesi
within
mycot
cell
flucytosin
partial
convert
cytostat
smaller
degre
reaction
expect
human
well
due
high
incid
resist
flucytosin
administ
combin
anoth
antifung
drug
amphotericin
b
anim
experi
fluycytosin
teratogen
effect
dose
use
human
yet
malform
report
human
howev
yet
publish
experi
use
flucytosin
first
trimest
case
report
applic
second
third
trimest
danger
dissemin
cryptococcosi
shown
evid
fetal
damag
eg
eli
griseofulvin
organ
deriv
antifung
agent
use
oral
sever
week
fungal
infect
skin
hair
nail
deposit
within
keratin
especi
suit
manag
fungal
infect
nail
mykos
anim
experi
griseofulvin
teratogen
high
dose
cancerogen
cross
placenta
term
rubin
one
public
base
birth
defect
data
report
two
pair
conjoin
twin
use
griseofulvin
earli
pregnanc
rosa
observ
could
confirm
public
knudsen
metneki
popul
base
casecontrol
studi
expos
pregnant
women
demonstr
increas
risk
malform
czeizel
experi
insuffici
differenti
risk
assess
recommend
insuffici
data
regard
use
echinocandin
pregnanc
use
altern
avail
mycosi
lifethreaten
treatment
took
place
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
recommend
flucytosin
use
lifethreaten
dissemin
fungal
infect
pregnanc
indic
monotherapi
need
assess
critic
use
second
mycot
drug
realli
necessari
treatment
took
place
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
recommend
griseofulvin
use
treat
lifethreaten
fungal
infect
applic
pregnanc
avoid
treatment
took
place
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
terbinafin
use
oral
topic
treatment
fungal
infect
nail
dermatophytos
prospect
studi
report
pregnant
women
expos
terbinafin
show
evid
teratogen
potenti
sarkar
women
expos
first
trimest
oral
exposur
data
insuffici
differenti
risk
analysi
use
topic
less
resorb
make
risk
unlik
regard
topic
use
azol
deriv
clotrimazol
miconazol
see
section
amphotericin
b
section
terbinafin
section
nystatin
antifung
drug
polyen
group
like
close
relat
amphotericin
b
bind
ergosterol
mycot
cell
wall
interfer
function
nystatin
effect
local
antifung
drug
candidiasi
skin
mucosa
taken
oral
poorli
resorb
work
local
intestin
tract
indic
intestin
cleans
need
critic
assess
immunocomprom
patient
nystatin
use
frequent
evid
embryoor
fetotox
effect
eg
king
populationbas
case
control
studi
show
increas
risk
malform
first
trimest
exposur
treatment
perform
second
third
trimest
slightli
case
hypospadia
note
czeizel
howev
low
resorpt
rate
methodolog
weak
studi
low
number
pregnant
women
place
result
question
retrospect
studi
hungarian
malform
regist
expos
subject
reveal
sign
increas
risk
malform
natamycin
appli
vagin
czeizel
base
regist
casecontrol
studi
discuss
possibl
associ
cardiovascular
malform
matern
use
tolnaft
pregnanc
czeizel
observ
base
expos
case
four
case
vari
type
cardiac
defect
ci
data
insuffici
differenti
risk
analysi
amorolfin
butenafin
ciclopirox
haloprogin
naftifin
tolcicl
insuffici
investig
regard
prenat
human
toxic
yet
substanti
indic
increas
risk
malform
local
use
recommend
terbinafin
avoid
pregnanc
safeti
data
lack
fungal
nail
infect
requir
urgent
treatment
treatment
took
place
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
topic
applic
like
harmless
recommend
nystatin
like
clotrimazol
miconazol
antifung
drug
choic
pregnanc
possibl
drug
prefer
extern
treatment
amorolfin
butenafin
ciclopirox
haloprogin
natamycin
naftifin
tolcicl
tolnaft
avoid
pregnanc
billion
peopl
infect
helminth
worldwid
soiltransmit
helminth
recogn
import
public
health
problem
mani
develop
countri
sever
hookworm
helminth
infect
pregnanc
may
caus
anemia
reduc
birth
weight
increas
perinat
mortal
routin
applic
anthelmint
second
third
trimest
women
area
endem
hookworm
infect
suggest
argument
may
improv
matern
anemia
birth
weight
neonat
mortil
eg
christian
howev
random
placebocontrol
studi
show
advantag
newborn
whose
pregnant
mother
receiv
albendazol
praziquantel
recent
discuss
routin
anthelmint
treatment
pregnanc
might
lead
increas
risk
allergi
infanc
mpairw
benzimidazol
deriv
albendazol
flubendazol
mebendazol
thiabendazol
triclabendazol
inhibit
uptak
glucos
therebi
kill
parasit
anim
experi
benzimidazol
deriv
anthelmint
activ
show
teratogen
effect
albendazol
mebendazol
poorli
resorb
gastrointestin
tract
except
inflamm
howev
enter
absorpt
may
increas
due
highfat
diet
mebendazol
highli
effect
well
toler
anthelmint
drug
use
nematod
pinworm
roundworm
whipworm
hookworm
report
describ
children
variou
malform
utero
exposur
mebendazol
distinct
pattern
malform
could
discern
review
schardein
increas
risk
congenit
malform
observ
studi
pregnant
women
expos
mebendazol
first
trimest
de
silva
confirm
control
prospect
studi
cover
first
trimest
expos
pregnant
women
diavcitrin
anoth
studi
first
trimest
exposur
also
found
increas
risk
malform
miscarriag
mcelhatton
although
number
small
definit
conclus
mebendazol
appear
repres
major
teratogen
risk
significantli
experi
collect
exposur
second
third
trimest
show
evid
fetal
risk
eg
gyorko
albendazol
newer
highli
effect
broadspectrum
anthelmint
combin
oper
intervent
becom
treatment
choic
alveolar
cystic
echinococcosi
limit
experi
first
trimest
shown
evid
major
risk
gyapong
cowden
sever
thousand
pregnanc
use
albendazol
second
third
trimest
without
obviou
advers
reaction
report
eg
ndyomugyenyi
two
abstract
korea
report
outcom
pregnant
women
first
trimest
exposur
flubendazol
show
evid
teratogen
potenti
choi
choi
howev
data
insuffici
differenti
risk
assess
report
thiabendazol
triclabendazol
use
human
pregnanc
ivermectin
broadspectrum
anthelmint
agent
mainli
use
human
treatment
onchocerciasi
river
blind
lymphat
filiriasi
strongyloidiasi
also
effect
worm
infect
epiderm
parasit
skin
diseas
scabi
ivermectin
well
resorb
oral
administr
anim
experi
suggest
teratogen
potenti
although
matern
toxic
exposur
malform
note
rodent
number
case
report
describ
accident
treatment
first
trimest
shown
malform
children
gyapong
chippaux
pacqu
howev
data
insuffici
differenti
risk
assess
studi
encompass
women
took
ivermectin
second
trimest
found
signific
anomali
newborn
ndyomugyenyi
niclosamid
anthelmint
effect
tapeworm
cestod
affect
energi
metabol
parasit
practic
resorb
intestin
tract
agent
use
extens
past
suspect
caus
malform
systemat
studi
human
praziquantel
highli
effect
broadspectrum
anthelmint
agent
mani
trematod
cestod
mainli
use
treatment
schistosomiasi
bilharziosi
teratogen
report
anim
studi
last
decad
million
pregnant
women
inadvert
treat
praziquatel
routin
anthelmint
program
without
obviou
advers
reaction
report
public
recommend
mebendazol
may
use
pregnanc
treat
relev
worm
diseas
albendazol
may
use
case
echinococcosi
benzimidazol
anthelmint
use
compel
indic
establish
anthelmint
ineffect
first
trimest
exposur
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
recommend
compel
indic
ivermectin
may
use
pregnanc
first
trimest
exposur
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
recommend
niclosamid
may
given
pregnanc
treat
relev
tapeworm
infect
applic
first
trimest
need
critic
assess
tapeworm
infect
gener
great
hazard
mother
unborn
child
first
trimest
exposur
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
also
found
evid
teratogen
potenti
mother
treat
first
trimest
adam
paparon
studi
uganda
encompass
pregnant
women
treatment
praziquantel
second
third
trimest
associ
increas
advers
outcom
ndibazza
recommend
use
praziquantel
schistosomiasi
pregnanc
pyrantel
broadspectrum
anthelmint
act
inhibit
cholinesteras
caus
spastic
paralysi
subsequ
death
parasit
teratogen
report
anim
studi
pyrantel
poorli
absorb
gastrointestin
tract
publish
experi
use
pregnanc
suffici
determin
risk
pyrvinium
effect
pinworm
enterobiu
oral
administr
hardli
absorb
therefor
unlik
reach
fetu
relev
amount
report
embryoor
fetotox
effect
howev
publish
experi
use
pyrvinium
pregnanc
danish
cohort
studi
base
prescript
regist
identifi
women
redeem
prescript
pyrvinium
first
trimest
pregnanc
outcom
consid
articl
torppedersen
diethylcarbamazin
use
treatment
filiriasi
onchocercosi
teratogen
report
anim
studi
public
regard
use
human
pregnanc
locat
levamisol
use
anthelmint
immunomodul
retrospect
studi
data
hungarian
malform
registri
base
subject
four
first
trimest
exposur
show
evid
increas
risk
malform
use
levamisol
kazi
oxamniquin
use
treatment
schistosomiasi
experi
report
use
pregnanc
recommend
praziquantel
reserv
specif
sever
indic
like
schistosomiasi
usual
indic
betterestablish
anthelmint
avail
first
trimest
exposur
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
recommend
pyrantel
avoid
pregnanc
better
test
altern
avail
indic
first
trimest
exposur
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
recommend
pyrvinium
may
use
pregnanc
standard
agent
group
acyclovir
use
varicellazost
viru
vzv
herp
simplex
viru
hsv
type
manufactur
case
collect
contain
women
treat
system
acyclovir
pregnanc
first
trimest
evid
embryoor
fetotox
risk
stone
studi
danish
registri
women
prescript
first
trimest
show
increas
risk
acyclovir
pasternak
although
studi
methodolog
weak
experi
argu
risk
acyclovir
pregnanc
valacyclovir
prodrug
acyclovir
convert
quickli
complet
acyclovir
bodi
oral
distinctli
better
resorb
acyclovir
resorb
manufactur
find
increas
risk
malform
women
receiv
valacyclovir
pregnanc
first
trimest
glaxo
wellcom
also
cite
studi
danish
registri
show
evid
embryoor
fetotox
risk
pregnanc
mother
fill
prescript
valacyclovir
first
trimest
pasternak
ganciclovir
prodrug
valganciclovir
effect
cytomegalu
viru
infect
cmv
anim
experi
teratogen
effect
seen
plasma
level
twice
high
recommend
human
therapi
case
report
describ
normal
pregnanc
outcom
first
trimest
treatment
earli
pregnanc
pescovitz
puliyanda
describ
success
oral
treatment
ganciclovir
intrauterin
cmv
infect
week
experi
insuffici
evalu
safeti
ganciclovir
pregnanc
famciclovir
quickli
convert
enter
resorpt
virostat
penciclovir
neou
report
newborn
whose
mother
took
mg
famciclovir
daili
fifth
week
boy
succumb
sever
neonat
infect
hypoplast
thymu
mild
stenosi
pulmonari
valv
ostium
secundum
defect
enlarg
liver
stenot
extrahepat
biliari
duct
retrospect
studi
data
danish
birth
registri
contain
women
took
oral
famciclovir
first
trimest
show
increas
malform
rate
pasternak
insuffici
data
use
pregnanc
brivudin
cidofovir
foscarnet
fomivirsen
anim
experi
small
dose
foscarnet
sodium
trigger
skelet
anomali
rat
rabbit
experi
report
combin
therapi
dimepranol
inosin
use
stimul
immun
system
virus
herp
group
recommend
diethylcarbamazin
levamizol
oxamniquin
avoid
pregnanc
better
test
altern
avail
indic
first
trimest
exposur
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
herp
medic
local
use
acyclovir
foscarnet
ganciclovir
idoxuridin
penciclovir
trifluridin
tromantadin
local
appli
hsv
infect
none
agent
suspect
give
rise
teratogen
effect
acyclovir
may
use
pregnanc
system
harmless
local
applic
cite
danish
registri
studi
women
use
acyclovir
women
penciclovir
local
first
trimest
increas
malform
risk
note
pasternak
agent
lack
studi
local
applic
docosanol
newli
approv
agent
topic
applic
herpet
cold
sore
mechan
action
unknown
experi
use
pregnanc
howev
risk
unlik
minim
resopt
local
applic
zinc
sulfat
patch
contain
hydrocolloid
particl
harmless
pregnanc
antivir
drug
hepat
antivir
drug
hepat
b
nucleosidenucleotid
analog
chapter
use
manag
chronic
hepat
b
gener
therapeut
recommend
made
pregnanc
data
inadequ
experi
far
reveal
seriou
sign
teratogen
fetotox
damag
human
activ
hepat
b
cirrhosi
antivir
treatment
might
consid
passiveact
immunoprophylaxi
infant
reduc
mothertochildtransmiss
howev
high
virem
mother
immunoprophylaxi
might
fail
consensu
reach
pregnant
women
hbsag
posit
highli
virem
treat
third
trimest
prevent
perinat
transmiss
infant
eg
pan
lamivudin
tenofovir
see
section
adefovir
dipivoxil
prodrug
adefovir
orallyadminist
nucleotid
analog
teratogen
report
anim
studi
antiretrovir
pregnanc
registri
receiv
report
birth
matern
adefovir
dipivoxil
regimen
first
trimest
birth
defect
observ
infant
entecavir
shown
teratogen
effect
anim
studi
high
dose
vertebr
tail
malform
occur
recommend
antivir
therapi
indic
sever
matern
diseas
protect
fetu
intrauterin
infect
acyclovir
valacyclovir
use
best
evalu
medic
whenev
possibl
antivir
agent
indic
infect
therapeut
advantag
acyclovir
applic
one
less
well
examin
drug
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
recommend
indic
local
remedi
herp
may
use
pregnanc
dri
agent
patch
herp
harmless
possibl
acyclovir
prefer
best
evalu
antivir
drug
infant
whose
mother
expos
entecavir
first
trimest
two
babi
born
birth
defect
detail
avail
antiretrovir
pregnanc
registri
one
case
report
describ
healthi
babi
born
entecavir
exposur
day
second
trimest
kakogawa
telbivudin
rais
suspicion
teratogen
anim
experi
among
pregnanc
women
receiv
telbivudin
earli
pregnanc
abort
rate
fifti
mother
deliv
infant
one
pregnanc
termin
cleft
lip
palat
one
infant
show
right
ear
accessori
birth
defect
report
liu
antiretrovir
pregnanc
registri
birth
defect
observ
infant
first
trimest
exposur
telbivudin
prospect
studi
infant
born
matern
treatment
telbivudin
late
pregnanc
prevent
perinat
transmiss
exposur
took
place
twentieth
thirtysecond
gestat
week
least
month
deliveri
signific
differ
infant
outcom
compar
control
group
seriou
advers
event
note
infant
ongo
discuss
whether
telbivudin
given
women
high
viru
load
late
pregnanc
prevent
intrauterin
transmiss
review
deng
nucleosid
analog
ribavirin
inhibit
dnaand
rnavirus
display
rel
broad
antivir
spectrum
experiment
among
applic
use
treat
respiratori
syncyti
viru
rsv
infect
infant
combin
chapter
hepat
c
ribavirin
teratogen
mutagen
effect
anim
experi
nine
women
treat
second
half
pregnanc
sever
measl
deliv
healthi
infant
atmar
woman
treat
sar
sever
acut
respiratori
syndrom
first
trimest
ribavirin
inject
day
gave
birth
normal
child
rezvani
pregnanc
registri
manufactur
note
eight
women
ribavirin
exposur
first
trimest
women
exposur
within
month
last
menstrual
period
robert
author
found
evid
teratogen
risk
human
summari
current
data
insuffici
risk
assess
ribavirin
embryoor
fetotox
risk
appar
avail
case
report
level
ribavirin
twice
high
semin
fluid
sperm
increas
risk
malform
patern
ribavirin
treatment
interferon
pregnanc
report
case
report
review
hofer
pregnanc
ribavirin
pregnanc
registri
robert
number
inadequ
assess
possibl
risk
patern
exposur
proteas
inhibitor
boceprevir
simeprevir
telaprevir
approv
treatment
chronic
hepat
c
experi
use
pregnanc
appli
sofosbuvira
recent
approv
polymeras
inhibitor
treatment
chronic
hepat
c
amantadin
enhanc
dopamin
activ
receptor
thu
also
use
antiparkinson
drug
antivir
medic
inhibit
membran
protein
hamper
abil
viru
enter
cell
nucleu
rapid
resist
frequent
neurolog
side
effect
recommend
antivir
agent
amantadin
parkinson
diseas
see
chapter
neuraminidas
inhibitor
oseltamivir
peramivir
zanamivir
use
treat
patient
whose
influenza
requir
therapi
oseltamivir
shown
teratogen
effect
anim
studi
prospect
investig
two
japanes
center
see
increas
malform
women
treat
first
trimest
review
tanaka
anoth
studi
involv
expos
offspr
first
trimest
also
find
higher
risk
greer
manufactur
notic
increas
risk
women
use
oseltamivir
pregnanc
first
month
donner
one
studi
pregnant
women
expos
oseltamivir
first
trimest
found
increas
risk
late
transient
hypoglycaemia
compar
unexpos
control
group
increas
risk
advers
birth
outcom
among
infant
observ
one
child
ventricular
septal
defect
major
malform
exposur
first
trimest
svensson
anoth
public
includ
pregnant
women
expos
oseltamivir
first
trimest
overal
rate
major
malform
first
trimest
exposur
saito
french
public
total
mother
receiv
least
one
prescript
oseltamivir
pregnanc
one
congenit
heart
defect
observ
among
infant
expos
first
trimest
signific
associ
advers
fetal
outcom
exposur
oseltamivir
pregnanc
could
found
beau
dunstan
could
also
find
sign
embryoor
fetotox
effect
expos
pregnant
women
birth
defect
observ
eight
first
trimest
exposur
populationbas
retrospect
cohort
studi
analyz
data
women
receiv
oseltamivir
pregnanc
compar
control
group
associ
matern
use
oseltamivir
preterm
birth
low
apgar
score
women
recommend
ribavirin
antivir
agent
discuss
use
pregnanc
compellingli
indic
treatment
first
trimest
justif
riskbas
termin
pregnanc
chapter
situat
detail
ultrasound
examin
offer
ascertain
normal
fetal
develop
pregnanc
took
oseltamivir
pregnanc
less
like
small
gestat
age
infant
howev
birth
defect
time
exposur
mention
xie
two
studi
look
pharmacokinet
oseltamivir
activ
metabolit
oseltamivir
carboxyl
gestat
greer
compar
pharmacokinet
pregnant
women
group
last
trimest
found
signific
differ
beigi
examin
pharmacokinetc
pregnant
women
averag
gestat
age
week
comparison
nonpregn
women
found
pregnant
group
lower
oseltamivir
carboxyl
level
howev
remain
unclear
dose
need
adjust
pregnanc
zanamivir
appli
inhal
littl
resorb
teratogen
found
anim
experi
case
seri
studi
japan
report
infant
born
intrauterin
zanamivir
exposur
expos
first
trimest
malform
observ
saito
prospect
surveil
studi
provid
case
use
zanamivir
pregnanc
associ
increas
risk
advers
pregnanc
outcom
among
women
expos
zanamivir
pregnanc
major
malform
report
zanamivir
first
trimest
exposur
dunstan
experi
presenc
low
system
concentr
make
unlik
increas
embryoor
fetotox
risk
experi
pregnanc
peramivir
insuffici
risk
assess
aim
antiretrovir
therapi
art
pregnanc
prevent
vertic
transmiss
human
immunodefici
viru
hiv
mother
child
also
optim
manag
hivinfect
mother
wherebi
unwant
side
effect
kept
minimum
child
art
pregnanc
becom
integr
part
prophylaxi
hiv
transmiss
data
reveal
protect
effect
perinat
prophylaxi
nucleosid
analog
revers
transcriptas
inhibitor
nrti
zidovudin
could
prevent
possibl
vertic
transmiss
last
trimest
labor
connor
nation
intern
guidelin
recommend
standard
therapi
nonpregn
pregnant
hivinfect
women
take
combin
least
three
antiretrovir
medic
eac
oarac
highli
activ
antiretrovir
therapi
haart
typic
consist
two
nrti
either
proteas
inhibitor
pi
nonnucleosid
analog
revers
transcriptas
inhibitor
nnrti
intent
suppress
plasma
hiv
load
hivrna
close
copiesml
least
end
pregnanc
effect
haart
appli
pregnanc
lactat
hiv
rate
transmiss
decreas
former
level
recommend
indic
neuraminidas
inhibitor
oseltamivir
tanamivir
may
use
pregnanc
peramivir
avoid
amantadin
longer
recommend
treatment
influenza
use
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
fetal
develop
townsend
warszawski
decis
regimen
use
alreadi
complic
nonpregn
patient
pregnanc
balanc
individu
need
risk
consid
especi
view
time
start
treatment
possibl
interrupt
therapi
first
trimest
women
alreadi
treatment
select
appropri
antiretrovir
medic
risk
intrauterin
exposur
combin
antiretrovir
agent
difficult
assess
data
limit
concern
pharmakinet
development
toxic
drug
data
longterm
toxic
exposur
intrauterin
retrovir
substanc
inform
safeti
retrovir
drug
pregnanc
limit
experi
anim
singl
case
report
clinic
studi
analys
registri
antiretrovir
pregnanc
registri
usa
contain
inform
safeti
antivir
substanc
pregnanc
overview
antiretrovir
medic
darunavir
fosamprenavir
indinavir
lopinavir
nelfinavir
ritonavir
saquinavir
tipranavir
entri
inhibitor
enfuvirtid
maraviroc
integras
inhibitor
raltegravir
dolutegravir
elvitegravir
data
current
avail
allow
summar
differenti
risk
analysi
antiretrovir
medic
pregnanc
except
efavirenz
seriou
sign
teratogen
fetotox
damag
human
eg
watt
ec
prospect
document
pregnanc
demonstr
higher
risk
malform
like
retrospect
case
report
fail
reveal
distinct
pattern
anomali
antiretrovir
agent
use
first
trimest
embryotox
risk
appear
gener
small
phiri
floridia
antiretrovir
pregnanc
registri
joao
nevertheless
substanc
might
embryotox
eschew
earli
pregnanc
common
side
effect
children
treat
utero
birth
zidovudin
antiretrovir
combin
consist
hematolog
problem
especi
anemia
neutropenia
drydenpeterson
feiternasperl
le
chenadec
debat
antiretrovir
treatment
without
proteas
inhibitor
favor
prematur
chen
patel
kourti
cotter
tuomala
matern
risk
therapi
discuss
specif
medic
medic
treatment
hiv
infect
pregnanc
prime
exampl
need
sometim
util
insuffici
test
medic
acut
danger
mother
child
individu
case
need
critic
assess
ongo
matern
indic
treatment
absolut
necessari
time
embryogenesi
temporarili
suspend
data
clinic
studi
pregnanc
women
avail
abacavir
didanosin
emtricitabin
lamivudin
stavudin
tenofovir
zidovudin
except
didanosin
nrti
show
compar
level
matern
serum
umbil
cord
blood
suggest
easi
placent
passag
pacifici
affin
mitochondri
polymeras
nrti
induc
mitochondri
dysfunct
greatest
risk
mitochondri
toxic
exhibit
vitro
didanosin
stavudin
zidovudin
question
perinat
nrti
exposur
could
lead
mitochondri
problem
children
current
discuss
final
consensu
reach
benhamm
blanch
lamivudin
zidovudin
nrti
prefer
pregnanc
extens
experi
abacavir
emtricitabin
tenofovir
altern
nrti
also
might
use
didanosin
stavudin
use
special
circumst
oarac
abacavir
lead
skelet
anomali
given
rat
high
dosag
evid
teratogen
human
abacavir
readili
cross
placenta
chappuy
data
antiretrovir
pregnanc
registri
birth
defect
case
indic
malform
rate
exposur
first
trimest
similarli
seen
gener
popul
usa
anim
experi
didanosin
given
high
dose
show
teratogen
effect
didanosin
cross
placenta
limit
recommend
antiretrovir
medic
may
use
pregnanc
specif
risk
prophylaxi
transmiss
therapi
matern
hiv
infect
need
observ
choic
medic
time
treatment
decid
individu
basi
choos
medic
note
retrovir
substanc
avoid
pregnanc
possibl
concern
efavirenz
teratogen
effect
combin
stavudinedidanosin
lactic
acidosi
newer
medic
maraviroc
raltegravir
etravirin
data
avail
concern
use
pregnanc
caution
call
nevirapin
use
women
cell
count
mm
hepatotox
nevirapin
use
pregnanc
transaminas
need
check
regularli
especi
first
week
treatment
also
clinic
symptom
watch
shortterm
use
nevirapin
transmiss
prophylaxi
seem
carri
similar
risk
exposur
occur
first
trimest
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
recommend
pregnant
patient
care
special
center
physician
report
pregnanc
involv
use
hiv
medic
shortli
diagnosi
antivir
pregnanc
registri
wwwapregistrycom
amount
wang
data
antiretrovir
pregnanc
registri
show
slightli
increas
malform
rate
first
trimest
exposur
birth
comparison
gener
us
popul
howev
distinct
pattern
birth
defect
discov
studi
hiv
infect
women
treat
week
didanosin
neither
matern
neonat
side
effect
note
wang
case
lethal
lactic
acidosi
describ
pregnant
women
treat
combin
stavudin
didanosin
mandelbrot
sarner
due
risk
fatal
lactic
acidosi
combin
treatment
didanosin
stavudin
use
case
altern
avail
bristolmy
squibb
emtricitabin
shown
evid
teratogen
anim
experi
human
cross
placenta
readili
stek
hirt
among
case
first
trimest
exposur
report
antiretrovir
pregnanc
registri
preval
birth
defect
birth
similar
rate
gener
us
popul
lamivudin
one
best
evalu
nrti
also
approv
treatment
chronic
hepat
b
level
measur
umbil
cord
blood
correspond
mother
data
antiretrovir
pregnanc
registri
indic
unsuspici
malform
rate
birth
larger
studi
prevent
perinat
transmiss
conduct
franc
pregnant
women
receiv
zidovudin
lamivudin
gestat
week
newborn
also
given
combin
week
mandelbrot
studi
newborn
display
signific
side
effect
includ
lethal
mitochondriopathi
howev
lamivudin
zidovudin
medic
prefer
pregnanc
extens
experi
evid
stavudin
lead
teratogen
effect
anim
experi
human
stavudin
cross
placenta
easili
chappuy
malform
rate
exposur
first
trimest
birth
accord
data
antiretrovir
pregnanc
registri
thu
similar
gener
us
popul
good
toler
staduvinelamivudin
combin
describ
small
phase
iii
studi
motherchild
pair
wade
case
lethal
lactic
acidosi
describ
pregnant
women
treat
combin
stavudin
didanosin
mandelbrot
sarner
due
risk
fatal
lactic
acidosi
combin
treatment
didanosin
stavudin
use
case
altern
avail
bristolmy
squibb
anim
experi
offspr
monkey
receiv
high
dose
tenofovir
decreas
fetal
growth
rate
diminish
fetal
bone
densiti
tarant
pregnanc
tenofovir
cross
placenta
easili
flynn
hirt
evid
tenofovir
teratogen
human
accord
data
antiretrovir
pregnanc
registri
malform
rate
exposur
first
trimest
birth
similar
rate
gener
us
popul
clinic
studi
hiv
patient
primarili
children
display
decreas
bone
densiti
treat
tenofovir
clinic
signific
find
still
unclear
one
studi
reveal
risk
advers
effect
utero
tenofovir
exposur
pregnant
women
gibb
howev
tenofovir
use
caution
pregnanc
risk
fetal
bone
chang
pauciti
data
pregnancyrel
risk
zidovudin
also
known
azidothymidin
azt
oldest
antivir
drug
use
antiretrovir
therapi
readili
cross
placenta
rat
matern
toxic
dose
lead
increas
malform
rate
organogenesi
effect
seen
lower
dose
sign
teratogen
human
accord
data
antiretrovir
pregnanc
registri
malform
rate
birth
signific
higher
gener
us
popul
applic
zidovudin
well
studi
pregnanc
consid
safe
regard
shortterm
mediumterm
toxic
common
side
effect
zidovudin
use
perinat
period
transient
anemia
newborn
sperl
connor
followup
studi
children
expos
zidovudin
utero
display
physic
immunolog
cognit
anomali
median
age
children
time
last
followup
year
rang
year
culnan
also
evid
increas
risk
neoplasia
children
preand
perinat
exposur
culnan
hanson
data
regard
longterm
toxic
especi
cancerogen
data
clinic
studi
safeti
human
pregnanc
nnrt
limit
nevirapin
agent
prefer
nnrti
requir
pregnanc
efavirenz
might
use
special
circumst
etravirin
rilpivirin
data
insuffici
recommend
use
pregnanc
oarac
delavirdin
recommend
part
initi
therapi
delavirdin
caus
increas
incid
ventricular
septal
defect
rat
experi
human
limit
birth
first
trimest
exposur
report
antiretrovir
pregnanc
registri
although
birth
defect
observ
data
allow
differenti
risk
analysi
guidelin
recommend
delavirdin
part
antiretrovir
regimen
initi
treatment
hiv
infect
inferior
efficaci
anim
experi
efavirenz
show
evid
teratogen
three
prenat
expos
cynomolgu
monkey
show
malform
plasma
level
similar
therapeut
level
human
anencephali
unilater
anophthalmia
observ
one
fetu
microphthalmia
anoth
cleft
palat
third
case
report
human
neural
tube
defect
children
whose
mother
receiv
efavirenz
first
trimest
de
santi
fundaro
accord
data
antiretrovir
pregnanc
registri
malform
rate
birth
first
trimest
exposur
compar
background
rate
gener
us
popul
birth
defect
includ
one
infant
myelomeningocel
anoth
child
born
anophthalmia
sever
facial
cleft
amniot
band
total
antiretrorvir
pregnanc
regist
receiv
six
retrospect
report
neural
tube
defect
four
expos
efavirenz
metaanalysi
includ
nine
prospect
studi
togeth
live
birth
detect
increas
risk
overal
birth
defect
exposur
efavirenzcontain
regimen
first
trimest
includ
retrospect
studi
one
neural
tube
defect
report
live
birth
ford
updat
metaanalysi
includ
addit
subject
similar
result
ford
contrast
reassur
find
anoth
studi
analyz
data
infant
born
significantli
increas
risk
congenit
anomali
exposur
efavirenz
first
trimest
observ
six
infant
first
trimest
exposur
efavirenz
congenit
anomali
adjor
ci
knapp
howev
six
observ
major
minor
defect
patent
foramen
oval
gastroschisi
postaxi
polydactyli
arnoldchiari
malform
talip
equinovaru
plagiocephali
present
distinct
pattern
avail
publish
experi
british
hiv
associ
guidelin
panel
conclud
insuffici
data
support
former
posit
furthermor
recommend
efavirenz
continu
commenc
pregnanc
taylor
howev
unit
state
guidelin
restrict
recommend
efavirenzbas
regimen
may
continu
women
present
antenat
care
first
trimest
provid
regimen
produc
virolog
suppress
oarac
anim
experi
shown
etravirin
teratogen
experi
pregnanc
limit
case
report
jaworski
furco
accord
data
antiretrovir
pregnanc
registri
birth
defect
report
infant
born
first
trimest
pregnanc
exposur
etravirin
experi
insuffici
analyz
possibl
risk
pregnanc
evid
anim
experi
human
experi
nevirapin
teratogen
nevirapin
cross
placenta
easili
attain
level
neonat
correspond
mother
benaboud
mirochnick
accord
data
antiretrovir
pregnanc
registri
malform
rate
first
trimest
exposur
birth
higher
gener
us
popul
studi
indic
viral
transmiss
block
mg
po
nevirapin
given
mother
begin
labor
newborn
receiv
singl
dose
mgkg
hour
deliveri
guay
high
risk
develop
viral
resist
even
singl
dose
low
resist
barrier
long
halflif
nevirapin
thu
nevirapin
administ
combin
regimen
report
publish
describ
singl
case
liver
toxic
pregnant
women
took
nevirapin
eg
knudtson
event
often
rashassoci
potenti
fatal
liver
toxic
primarili
observ
patient
higher
cell
count
patient
risk
symptomat
hepat
event
twelv
time
greater
women
lower
cell
count
studi
indic
pregnanc
per
se
risk
factor
liver
toxic
pregnant
patient
use
haart
includ
nevirapin
higher
risk
hepatotox
use
haart
without
nevirapin
ouyang
ouyang
data
suggest
risk
liver
toxic
nevirapin
similar
pregnant
nonpregn
patient
howev
nevirapin
use
pregnanc
physician
awar
hepatotox
anim
experi
fail
show
rilpivirin
teratogen
antiretrovir
pregnanc
registri
birth
defect
report
infant
born
first
trimest
exposur
rilpivirin
one
public
describ
two
healthi
infant
rilpivirin
exposur
pregnanc
colber
experi
insuffici
analyz
possibl
risk
pregnanc
pi
use
increasingli
pregnanc
recommend
regimen
combin
two
nrti
drug
pi
therapi
lead
disturb
glucos
toler
even
manifest
exacerb
diabet
mellitu
remain
unclear
pregnanc
increas
risk
even
gener
pi
pass
placenta
poorli
gingelmai
marzolini
mirochnick
therefor
fetal
toxic
would
seem
unlik
lopinavirritonavir
atazanavir
lowdos
ritonavir
boost
prefer
pi
pregnanc
altern
pi
includ
ritonavirboost
saquinavir
darunavir
indinavir
nelfinavir
use
special
circumst
data
limit
recommend
routin
use
fosamprenavir
tipranavir
pregnant
women
oarac
atazanavir
shown
evid
teratogen
anim
experi
human
experi
accord
data
antiretrovir
pregnanc
registri
malform
rate
birth
first
trimest
exposur
compar
rate
gener
us
popul
number
studi
avail
includ
pharmacokinet
evalu
pregnant
women
use
haart
atazanavir
ripamonti
expert
recommend
increas
dose
late
pregnanc
umbil
cord
blood
neonat
show
atazanavir
level
seen
matern
serum
atazanavir
inhibit
uridin
glucuronosyl
transferas
metabol
indirect
bilirubin
thu
common
side
effect
atazanavir
treatment
may
lead
higher
indirect
bilirubin
level
case
number
rel
small
investig
show
neonat
atazanavirtr
mother
show
patholog
elev
indirect
bilirubin
ripamonti
darunavir
demonstr
evid
teratogen
anim
experi
case
report
demonstr
limit
placent
transfer
like
pi
reduct
plasma
level
observ
late
pregnanc
pinnetti
antiretrovir
pregnanc
registri
five
birth
defect
report
infant
born
first
trimest
exposur
rilpivirin
preval
experi
use
pregnanc
avail
eg
jaworski
ivanov
data
insuffici
differenti
risk
assess
anim
experi
evid
found
fosamprenavir
lead
teratogen
human
data
use
pregnanc
limit
transplacent
passag
analyz
seven
case
rel
high
compar
pi
author
detect
median
ratio
cord
blood
matern
amprenavir
level
activ
metabolit
fosamprenavir
cesped
one
public
report
advers
effect
nine
infant
intrauterin
exposur
fosamprenavir
martorel
two
birth
defect
among
birth
report
antiretrovir
pregnanc
registri
first
trimest
exposur
fosamprenavir
data
insuffici
differenti
risk
assess
evid
teratogen
evid
indinavir
anim
experi
human
report
littl
indinavir
cross
placenta
mirochnick
accord
data
antiretrovir
pregnanc
pregnanc
registri
malform
rate
birth
first
trimest
exposur
compar
gener
us
popul
data
insuffici
differenti
risk
assess
theoret
concern
physiolog
hyperbilirubinemia
might
exacerb
due
indinavir
lopinavir
use
conjunct
pharmacolog
booster
ritonavir
anim
experi
high
dose
lopinavir
rat
display
evid
embryotox
increas
rate
miscarriag
less
fetal
viabil
lower
fetal
weight
skelet
chang
problem
appar
rabbit
evid
teratogen
human
like
pi
lopinavirritonavir
cross
placenta
poorli
gingelmai
accord
data
antiretrovir
pregnanc
registri
malform
rate
birth
first
trimest
exposur
thu
increas
comparison
gener
us
popul
studi
hivinfect
pregnant
women
indic
treatment
lopinavirritonavir
well
toler
pharmacokinet
investig
show
lower
plasma
level
primarilti
last
trimest
best
unclear
pregnant
women
requir
higher
dose
continu
pi
standard
therapi
report
infant
receiv
lopinavir
ritonavir
birth
observ
associ
transient
adren
dysfunct
infant
simon
systemat
review
safeti
efficaci
lopinavirritonavir
pregnanc
includ
nine
studi
involv
pregnant
women
concern
use
agent
suggest
pasley
nelfinavir
display
evid
teratogen
anim
experi
accord
data
antiretrovir
pregnanc
registri
malform
rate
birth
first
trimest
exposur
modest
evalu
compar
gener
popul
distinct
pattern
birth
defect
defect
discov
studi
hivinfect
pregnant
women
note
small
amount
cross
placenta
bryson
mirochnick
nelfinavir
use
unboost
pi
pregnant
women
need
treatment
hiv
inferior
newer
lowdos
ritonavir
boost
pi
use
altern
pi
combin
nrti
prophylaxi
hiv
transmiss
howev
nevirapin
use
special
circumst
pregnanc
ritonavir
use
combin
pi
lowdos
booster
increas
level
second
pi
small
amount
cross
placenta
mirochnick
evid
ritonavir
teratogen
anim
experi
human
accord
data
antiretrovir
pregnanc
registri
malform
rate
birth
first
trimest
exposur
thu
similar
gener
us
popul
saquinavir
demonstr
evid
teratogen
anim
experi
human
experi
like
pi
small
amount
drug
cross
placenta
mirochnick
pharmacokinet
studi
indic
newer
tablet
formul
replac
former
capsul
formul
lead
plasma
concentr
similar
nonpregn
patient
van
der
lugt
thu
necessari
adjust
dose
pregnanc
seven
birth
defect
among
first
trimest
exposur
report
antiretrovir
pregnanc
registri
data
insuffici
differenti
risk
assess
tipranavir
show
teratogen
anim
experi
data
abil
cross
placenta
asid
singl
case
report
pregnant
patient
multipl
resist
weizsaeck
wens
data
use
tipranavir
pregnanc
birth
defect
report
antiretrovir
pregnanc
registri
among
four
first
trimest
exposur
tipranavir
experi
insuffici
analyz
possibl
risk
pregnanc
entri
inhibitor
antiretrovir
agent
inhibit
viral
bind
fusion
hiv
cell
either
inhibit
fusion
viral
capsul
cell
membran
block
coreceptor
data
use
enfuvirtid
maravorioc
pregnanc
insuffici
recommend
use
pregnanc
oarac
anim
experi
evid
observ
enfuvirtid
teratogen
number
singl
case
report
suggest
enfuvirtid
appar
cross
placenta
weizsaeck
brennanbenson
accord
data
antiretrovir
pregnanc
registri
birth
defect
report
among
first
trimest
exposur
enfuvirtid
thu
assum
risk
fetal
toxic
like
small
enfuvirtid
may
use
pregnant
women
multiresist
hiv
combin
potent
agent
therapeut
option
current
experi
pregnanc
limit
maraviroc
inhibitor
use
treat
pretreat
hivinfect
adult
combin
antiretrovir
medic
exclus
hiv
proven
present
anim
experi
use
rat
rabbit
show
evid
teratogen
maraviroc
data
indic
degre
pregnanc
maraviroc
cross
placenta
indic
use
maraviroc
lead
higher
rate
malign
theoret
concern
remain
base
method
action
maraviroc
use
benefit
justifi
potenti
fetal
risk
lack
data
applic
pregnanc
among
case
first
trimest
exposur
report
antiretrovir
pregnanc
registri
birth
defect
observ
integras
inhibitor
block
integras
hivcod
enzym
therebi
hiv
replic
use
raltegravir
pregnanc
consid
special
circumst
prefer
altern
agent
use
oarac
insuffici
data
new
integras
inhibitor
dolutegravir
elvitegravir
anim
experi
evid
seen
dolutegravir
teratogen
placent
transfer
describ
anim
experi
report
use
human
pregnanc
also
report
use
dolutegravir
antiretrovir
pregnanc
registri
elvitegravir
combin
colbicistat
known
antiretrovir
activ
colbicistat
pharmacokinet
enhanc
inhibit
enzym
metabol
elvitegravir
anim
studi
elvitegravir
shown
evid
teratogen
one
report
use
elvitagravir
first
trimest
report
antiretrovir
pregnanc
registri
birth
defect
observ
case
develop
studi
rat
rabbit
show
raltegravir
teratogen
howev
slightli
increas
incid
supernumerari
rib
offspr
rat
receiv
raltegravir
dose
time
higher
recommend
human
treatment
potenti
human
risk
known
time
accord
data
use
pregnanc
raltegravir
cross
placenta
well
mckeown
case
seri
five
women
raltegravir
well
toler
taylor
three
birth
defect
observ
among
pregnant
women
first
trimest
exposur
report
antiretrovir
pregnanc
registri
experi
increas
unit
state
guidelin
recommend
allow
regimen
includ
raltegravir
special
circumst
prefer
altern
agent
use
oarac
howev
data
use
raltegravir
pregnanc
allow
differenti
risk
analysi
year
ago
anim
experi
demonstr
increas
bodi
temperatur
caus
malform
review
graham
edward
miller
problem
also
discuss
human
neural
tube
defect
particular
suarez
shaw
also
kidney
heart
abdomin
wall
defect
abe
chamber
report
associ
febril
infect
earli
pregnanc
even
though
overal
malform
risk
absent
mildli
increas
moretti
perform
metaanalysi
risk
neural
tube
defect
hyperthermia
includ
studi
case
found
signific
correl
ci
nine
casecontrol
studi
six
cohort
studi
lower
fever
pregnant
women
seem
reduc
risk
suarez
debat
use
sauna
electr
blanket
factor
bring
shortterm
increas
bodi
temperatur
could
lead
similar
effect
high
fever
suarez
finland
issu
investig
repeatedli
visit
sauna
occur
frequent
pregnanc
consid
safe
use
electr
blanket
heat
water
bed
shown
investig
link
increas
malform
risk
one
studi
observ
children
age
frequent
emot
cognit
deficit
report
high
fever
second
third
trimest
dombrowski
summari
appear
slightli
higher
risk
malform
high
fever
hour
occur
especi
first
week
concept
longdist
travel
flight
pregnanc
number
potenti
risk
need
consid
prevent
infect
malaria
prophylaxi
see
section
vaccin
see
chapter
risk
infect
fever
fluid
loss
requir
therapi
longdist
flight
risk
thrombosi
ioniz
cosmic
radiat
recommend
infect
high
fever
especi
earli
pregnanc
fever
control
acetaminophen
paracetamol
ibuprofen
chapter
ibuprofen
taken
gestat
week
non
pharmacolog
measur
fever
control
cool
wrap
suffici
fluid
intak
also
consid
case
high
fever
episod
earli
pregnanc
detail
ultrasound
examin
offer
ascertain
normal
develop
fetu
fever
episod
justifi
riskbas
termin
pregnanc
chapter
visit
sauna
limit
less
minut
hot
long
bath
need
avoid
well
sourc
overheat
bodi
decreas
partial
oxygen
pressur
equival
altitud
dri
air
physic
psycholog
stress
specif
development
anomali
found
pregnant
women
undergo
vaccin
recommend
malaria
prophylaxi
problem
seen
result
longdist
flight
howev
need
note
stress
longdist
trip
especi
predispos
women
might
increas
risk
miscarriag
also
asid
typic
infecti
diseas
common
infect
may
preval
due
alter
hygien
standard
destin
countri
accompani
dehydr
fever
complic
may
also
endang
fetu
dose
cosmic
radiat
longdist
flight
vari
markedlydepend
solar
activ
yet
accord
current
knowledg
dose
reach
high
enough
lead
increas
risk
malform
